{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yuan Y"],"funding":["Shanghai Science and Technology Innovation Fund","National Science & Technology Major Project \"Key New Drug Creation and Manufacturing Program\", China"],"pagination":["837"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9866629"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(2)"],"pubmed_abstract":["Novel furoxan/coumarin hybrids were synthesized, and pharmacologic studies showed that the compounds displayed potent antiproliferation activities via downregulating both the phosphatidylinositide 3-kinase (PI3K) pathway and the mitogen-activated protein kinase (MAPK) pathway. To investigate the preclinical pharmacokinetic (PK) properties of three candidate compounds (CY-14S-4A83, CY-16S-4A43, and CY-16S-4A93), liquid chromatography, in tandem with the mass spectrometry LC-MS/MS method, was developed and validated for the simultaneous determination of these compounds. The absorption, distribution, metabolism, and excretion (ADME) properties were investigated in in vitro studies and in rats. Meanwhile, physiologically based pharmacokinetic (PBPK) models were constructed using only in vitro "],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model."],"pmcid":["PMC9866629"],"funding_grant_id":["18140900900","2018ZX09711002"],"pubmed_authors":["Tang Z","Li Z","Liu L","Peng C","Zhu X","Chen Y","Xiang X","Zhang S","He Q","Wang K","Yuan Y","Cai W"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model.","description":"Novel furoxan/coumarin hybrids were synthesized, and pharmacologic studies showed that the compounds displayed potent antiproliferation activities via downregulating both the phosphatidylinositide 3-kinase (PI3K) pathway and the mitogen-activated protein kinase (MAPK) pathway. To investigate the preclinical pharmacokinetic (PK) properties of three candidate compounds (CY-14S-4A83, CY-16S-4A43, and CY-16S-4A93), liquid chromatography, in tandem with the mass spectrometry LC-MS/MS method, was developed and validated for the simultaneous determination of these compounds. The absorption, distribution, metabolism, and excretion (ADME) properties were investigated in in vitro studies and in rats. Meanwhile, physiologically based pharmacokinetic (PBPK) models were constructed using only in vitro ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T10:19:58.565Z","creation":"2025-02-19T00:12:47.584Z"},"accession":"S-EPMC9866629","cross_references":{"pubmed":["36677893"],"doi":["10.3390/molecules28020837"]}}